The nature of liposomes is phospholipid and cholesterol, which makes them biologically inert, non-immunogenic, and biodegradable, with low intrinsic toxicity. Therefore, they become more potential drug delivery carriers. Despite their lipophilic properties, liposomes are very large and cannot simply diffuse to the cell membrane or between blood brain barrier (BBB) cells. Instead, liposomes cross the BBB via transport systems such as adsorptive-mediated transcytosis (AMT), receptor-mediated transcytosis (RMT), and carrier-mediated transports (CMT). In a sense, liposomes themselves add physiological interactions to the physiological interactions of drugs, thus affecting drug distribution characteristics. Liposomes were designed and optimized to make them more suitable for drug delivery. Ace Therapeutics provides comprehensive services from different perspectives to optimize liposome - based drug delivery systems for stroke treatment.
The first step in establishing a liposome drug delivery system is to prepare liposomes. Ace Therapeutics provides comprehensive services to prepare liposomal formulations. Common preparation methods include the passive drug loading method and the active drug loading method.
Through surface functionalization and other technologies, some liposomal transport systems utilizing BBB have been developed to efficiently deliver drugs to the brain. Ace Therapeutics provides comprehensive services to develop appropriate liposomal transport systems for stroke pathology.
After obtaining liposome preparations, it is very important to evaluate them in vitro and in vivo. Studies have shown that empty liposomes can affect drug BBB transport in a drug-dependent manner. Therefore, the activity evaluation of liposome preparations determines the value of candidate preparations. Therefore, Ace Therapeutics offers a range of services to test the activity of liposome preparations.
Ace Therapeutics offers comprehensive services to measure the ability of liposomal drugs to cross the BBB while performing pharmacokinetic testing of liposomal drugs.
If you would like to learn more about our services, please feel free to contact us.
We are committed to accelerating progress in stroke research and drug development.